Immunome Stock Surges 20% After Positive Phase 3 Data For Desmoid Tumor Drug

Immunome shares jumped 20.44% to close at $23.57 after the company reported positive topline Phase 3 RINGSIDE results for varegacestat in desmoid tumors, with the study meeting its primary endpoint—showing a statistically significant and clinically meaningful reduction in tumor volume versus placebo—and delivering favorable secondary outcomes. The data position varegacestat as a potential best-in-class oral treatment for a rare, hard-to-treat condition, meaningfully de-risking the program ahead of potential regulatory discussions and supporting Immunome's transition to a late-stage clinical company with a near-term regulatory catalyst. Shares trade within a 52-week range of roughly $7.50–$25.10, reflecting investor optimism about the drug's commercial potential.

Analysis

Immunome shares jumped 20.44%, rising $4.00 to close at $23.57 after the company announced positive topline Phase 3 RINGSIDE results for varegacestat in patients with desmoid tumors. The study met its primary endpoint with a statistically significant and clinically meaningful reduction in tumor volume versus placebo and reported favorable secondary outcomes, positioning the asset as a potential best-in-class oral treatment for a rare, difficult-to-treat indication.

The topline readout meaningfully de-risks the program ahead of potential regulatory discussions and supports Immunome's transition into a late-stage clinical company with a near-term regulatory catalyst. Market reaction—shares trading within a 52-week range of approximately $7.50–$25.10 and the 20% intraday surge—reflects investor enthusiasm about commercial potential but also suggests expectations are now being priced in.

The article does not disclose detailed safety data, durability of response, or specific secondary endpoint metrics, leaving uncertainty around label, population, and regulatory timing. Investors should expect the next material events to be full data release, regulatory meeting disclosures, and any guidance on filing strategy or commercialization assumptions before raising conviction materially.

Key Decisions for Investors

• Consider tactical exposure to IMNM to capture upside into the full data release and potential regulatory milestones, but size positions conservatively given limited topline detail
• Wait for the complete Phase 3 dataset—including safety, durability, and subgroup analyses—before increasing conviction or treating the asset as de-risked for commercialization
• If already long, hedge part of the position with options or other downside protection to lock in gains ahead of binary regulatory outcomes
• Monitor management guidance on regulatory filing plans, commercial assumptions, and potential partnerships; reassess valuation once those inputs and the full dataset are public